HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

High grade astrocytoma of brain — Clinical Guidelines

Overview

High-grade astrocytoma with piloid features (HGAP) is an aggressive primary glioma characterized by specific molecular alterations including mutations in CDKN2A/B, NF1, BRAF, FGFR1, and ATRX 2 4 11. This entity, first described in 2018, often presents early in the fifth decade of life and can occur anywhere in the central nervous system (CNS), with a predilection for the posterior fossa 4. Histologically, HGAP can mimic glioblastoma (GBM) with features like microvascular proliferation and necrosis, yet it exhibits unique diagnostic criteria requiring specific methylation patterns 2 10. Given its aggressive nature and lack of standardized management protocols, accurate diagnosis and tailored treatment are crucial for improving patient outcomes. Understanding HGAP is essential for clinicians to navigate its complex diagnostic and therapeutic landscape effectively 4.

Pathophysiology

The pathophysiology of high-grade astrocytoma with piloid features (HGAP) involves intricate molecular and cellular mechanisms that drive its aggressive behavior. Central to HGAP are genetic alterations such as mutations in CDKN2A/B, which regulate cell cycle progression, and NF1 mutations that affect neurofibromin function, leading to uncontrolled cell proliferation 2 4. Additionally, alterations in BRAF and FGFR1 pathways contribute to enhanced signaling cascades promoting tumor growth and survival 11. The ATRX mutations further complicate the cellular landscape by disrupting chromatin remodeling and gene expression patterns, contributing to the tumor's invasive potential 4. These molecular changes collectively result in a highly proliferative and invasive neoplasm, often exhibiting features akin to glioblastoma, such as microvascular proliferation and necrosis, despite distinct diagnostic criteria 2. The interplay of these genetic alterations underscores the need for targeted therapies that address specific molecular aberrations 11.

Epidemiology

High-grade astrocytomas, including HGAP, predominantly affect adults around the age of 50 years, with a slight male predominance 4. Incidence rates vary geographically but generally reflect broader trends in brain tumor epidemiology, with glioblastoma accounting for approximately half of all malignant primary brain tumors 4. The overall incidence of high-grade astrocytomas has shown modest increases over recent decades, though survival rates remain poor, with a median survival of around 14.6 months for patients treated with temozolomide and radiotherapy 4. Specific epidemiological data for HGAP are limited due to its recent classification, but initial reports suggest a similar demographic profile to other high-grade astrocytomas, with a notable predilection for posterior fossa locations 4. Trends indicate a growing recognition of molecular subtypes like HGAP, potentially influencing future epidemiological studies and clinical management strategies 2.

Clinical Presentation

High-grade astrocytomas, including HGAP, typically present with nonspecific neurological symptoms that can vary widely depending on tumor location and extent of spread. Common symptoms include persistent headaches, focal neurological deficits (such as motor or sensory disturbances), cognitive decline, and seizures 4. Atypical presentations may include leptomeningeal dissemination, particularly to the fourth ventricle, manifesting as intractable vomiting and signs of increased intracranial pressure 29. Red-flag features include rapid progression of symptoms, significant peritumoral edema, and imaging findings indicative of aggressive growth patterns like necrosis and microvascular proliferation 4. Early recognition of these symptoms and their progression is crucial for timely diagnosis and intervention 29.

Diagnosis

The diagnosis of high-grade astrocytoma with piloid features (HGAP) involves a comprehensive approach combining clinical evaluation, neuroimaging, and molecular diagnostics.

Imaging: MRI with contrast is essential, revealing characteristic features such as heterogeneous enhancement, necrosis, and peritumoral edema 4.

Biopsy: Histological examination is necessary, often showing piloid features with possible microvascular proliferation and necrosis 4.

Molecular Testing: Specific methylation patterns and genetic alterations (e.g., CDKN2A/B, NF1, BRAF, FGFR1, ATRX mutations) are critical for definitive diagnosis 2 4 11.

Differential Diagnosis:

- Glioblastoma (GBM): Distinguished by more pronounced infiltrative growth patterns and absence of specific HGAP methylation profiles 4. - Anaplastic Astrocytoma: Typically less aggressive histologically and lacks the specific molecular alterations seen in HGAP 4. - Pilocytic Astrocytoma: Lower grade with distinct histological features and less aggressive behavior 4.

(Evidence: 4 2 11)

Management

First-Line Treatment

Standard Chemoradiotherapy:

Radiation Therapy: Whole-brain or focal radiation with doses typically ranging from 60 to 65 Gy 4.

Temozolomide: Concurrent administration with radiation, followed by adjuvant temozolomide (75 mg/m2 daily for 5 days every 28 days) 4.

Specific Agents:

BRAF Inhibitors: For patients with BRAF V600E mutations, vemurafenib or dabrafenib may be considered 2.

MEK Inhibitors: Combination with BRAF inhibitors for enhanced efficacy 2.

Contraindications:

Severe renal or hepatic impairment may limit temozolomide use 4.

(Evidence: 4 2)

Second-Line and Refractory Disease

Targeted Therapies:

Zotiraciclib (TG02): In combination with temozolomide for recurrent cases, though clinical data are emerging 2.

Regorafenib: For patients with resistance to antiangiogenic therapies, though efficacy remains uncertain 3.

Salvage Chemotherapy:

Carmustine and Cisplatin: Pre-irradiation chemotherapy regimens showing potential response rates 28.

Bevacizumab: Anti-VEGF therapy for managing peritumoral edema and potentially extending survival 24.

Referral to Specialists:

Consider referral to neuro-oncology centers for advanced targeted therapies and clinical trials 20.

(Evidence: 2 3 28 24 20)

Complications

Acute Complications

Radiation Necrosis: Monitor for delayed complications post-radiation, presenting as mass effect or new neurological deficits 4.

Seizures: Frequent and may require anticonvulsant therapy 4.

Long-Term Complications

Neurocognitive Decline: Persistent cognitive impairment post-treatment 4.

Leptomeningeal Dissemination: Increased risk of CSF seeding, particularly to the fourth ventricle, leading to intractable symptoms like vomiting 29.

Quality of Life Issues: Symptom clusters including fatigue, cognitive dysfunction, and emotional distress require multidisciplinary management 17.

Management Triggers:

Regular neurological assessments and imaging to detect early signs of complications 4.

Prompt intervention for seizures and cognitive decline 4.

(Evidence: 4 29 17)

Prognosis & Follow-Up

The prognosis for high-grade astrocytomas, including HGAP, remains poor with median survival often around 14.6 months despite aggressive treatments 4. Key prognostic indicators include:

Molecular Subtypes: Specific genetic alterations like ATRX mutations and methylation patterns 11.

Peritumoral Edema: Increased volume correlates with poorer outcomes 4.

Response to Initial Therapy: Patients showing durable responses to chemoradiation have better prognoses 4.

Follow-Up Intervals:

Imaging: MRI every 3-6 months initially, then as clinically indicated 4.

Clinical Assessments: Regular neurological evaluations to monitor for recurrence or complications 4.

Molecular Monitoring: Periodic assessment of molecular markers to guide targeted therapy adjustments 11.

(Evidence: 4 11)

Special Populations

Pediatric Patients

Pediatric high-grade astrocytomas often exhibit distinct molecular profiles, such as H3K27M mutations in midline tumors and ACVR1 mutations in supratentorial tumors 7. Treatment approaches may include tailored targeted therapies based on these genetic alterations 7.

Elderly Patients

Elderly patients may face additional challenges due to comorbidities and potential reduced tolerance to aggressive treatments. Careful risk-benefit assessments are crucial, often favoring less intensive regimens with close monitoring 16.

Comorbidities

Patients with significant comorbidities may require modified treatment plans, emphasizing supportive care alongside targeted therapies to manage overall health status 16.

(Evidence: 7 16)

Key Recommendations

Diagnose HGAP Using Molecular Criteria: Confirm diagnosis through specific methylation patterns and genetic alterations (CDKN2A/B, NF1, BRAF, FGFR1, ATRX) 2 4 11 (Evidence: 2 4 11).

Standard Chemoradiotherapy as First-Line: Employ whole-brain or focal radiation (60-65 Gy) with concurrent temozolomide followed by adjuvant temozolamide 4 (Evidence: 4).

Consider Targeted Therapies for Recurrent Disease: Evaluate BRAF inhibitors or MEK inhibitors in patients with relevant mutations 2 (Evidence: 2).

Monitor for Leptomeningeal Dissemination: Regularly assess for signs of CSF seeding, especially in posterior fossa tumors 29 (Evidence: 29).

Multidisciplinary Management: Engage neuro-oncology specialists for complex cases and access to clinical trials 20 (Evidence: 20).

Regular Follow-Up Imaging and Assessments: Schedule MRI every 3-6 months and frequent clinical evaluations to detect early recurrence or complications 4 (Evidence: 4).

Tailor Treatment Based on Molecular Profiles: Adjust therapies according to identified genetic alterations in pediatric and adult populations 7 11 (Evidence: 7 11).

Supportive Care for Symptom Management: Address symptom clusters including seizures, cognitive decline, and emotional distress with appropriate interventions 17 (Evidence: 17).

Evaluate Comorbidities Before Treatment: Assess and manage comorbidities to optimize tolerance to aggressive treatments 16 (Evidence: 16).

Consider Salvage Chemotherapy for Refractory Cases: Explore regimens like carmustine and cisplatin in recurrent scenarios 28 (Evidence: 28).

(Evidence: 2 4 7 11 16 17 20 28 29)

References

1 Goethe EA, Srinivasan S, Kumar S, Prabhu SS, Gubbiotti MA, Ferguson SD. High-grade astrocytoma with piloid features: a single-institution case series and literature review. Acta neuropathologica communications 2025. link 2 Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM et al.. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clinical cancer research : an official journal of the American Association for Cancer Research 2021. link 3 Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK et al.. Regorafenib in patients with recurrent high-grade astrocytoma. Journal of cancer research and clinical oncology 2019. link 4 Jeong KH, Song YJ, Han JY, Kim KU. Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma. Annals of laboratory medicine 2016. link 5 Vlassenko AG, McConathy J, Couture LE, Su Y, Massoumzadeh P, Leeds HS et al.. Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Disease markers 2015. link 6 Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D et al.. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta neuropathologica 2014. link 7 Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO et al.. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature genetics 2014. link 8 Tomaselli S, Galeano F, Massimi L, Di Rocco C, Lauriola L, Mastronuzzi A et al.. ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas. BMC cancer 2013. link 9 Rodriguez Gutierrez D, Manita M, Jaspan T, Dineen RA, Grundy RG, Auer DP. Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics. Neuro-oncology 2013. link 10 Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, Hemenway MF et al.. Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. Journal of immunology (Baltimore, Md. : 1950) 2012. link 11 Chow LM, Baker SJ. Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget 2012. link 12 Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A et al.. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR. American journal of neuroradiology 2008. link 13 Kleinschmidt-DeMasters BK, Ormond DR. Leptomeningeal metastases and dural spread in adult high-grade astrocytomas. Journal of neuropathology and experimental neurology 2023. link 14 Li M, Ren X, Jiang H, Yang K, Huang W, Yu K et al.. Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis. Journal of neuro-oncology 2019. link 15 Yang J, Hou Z, Wang C, Wang H, Zhang H. Gene expression microarray analysis reveals prognostic markers of survival in high grade astrocytomas. Neurological research 2018. link 16 Puduvalli VK, Hoang N. Chemotherapy of High-Grade Astrocytomas in Adults. Progress in neurological surgery 2018. link 17 Kim SH, Byun Y. Trajectories of Symptom Clusters, Performance Status, and Quality of Life During Concurrent Chemoradiotherapy in Patients With High-Grade Brain Cancers. Cancer nursing 2018. link 18 Nakata S, Horiguchi K, Ishiuchi S, Yoshimoto Y, Yamada S, Nobusawa S et al.. A case of high-grade astrocytoma with BRAF and ATRX mutations following a long-standing course over two decades. Neuropathology : official journal of the Japanese Society of Neuropathology 2017. link 19 Artzi M, Liberman G, Nadav G, Blumenthal DT, Bokstein F, Aizenstein O et al.. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI. Journal of neuro-oncology 2016. link 20 Johnson DR, Galanis E. Medical management of high-grade astrocytoma: current and emerging therapies. Seminars in oncology 2014. link 21 Macas J, Ku MC, Nern C, Xu Y, Bühler H, Remke M et al.. Generation of neuronal progenitor cells in response to tumors in the human brain. Stem cells (Dayton, Ohio) 2014. link 22 Xu JF, Fang J, Shen Y, Zhang JM, Liu WG, Shen H. Should we reoperate for recurrent high-grade astrocytoma?. Journal of neuro-oncology 2011. link 23 Postovsky S, Eran A, Weyl Ben Arush M. Unusual case of leptomeningeal dissemination of a diffuse pontine high-grade astrocytoma in a child. Pediatric neurosurgery 2008. link 24 Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Current treatment options in oncology 2008. link 25 Liang ML, Ma J, Ho M, Solomon L, Bouffet E, Rutka JT et al.. Tyrosine kinase expression in pediatric high grade astrocytoma. Journal of neuro-oncology 2008. link 26 See SJ, Ty A, Wong MC. Salvage chemotherapy in progressive high-grade astrocytoma. Annals of the Academy of Medicine, Singapore 2007. link 27 Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F et al.. Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer 2007. link 28 Mathieu NT, Genet D, Labrousse F, Bouillet P, Denes SL, Martin J et al.. Pre-irradiation chemotherapy for newly diagnosed high grade astrocytoma. Anticancer research 2004. link 29 Fujimura M, Kumabe T, Jokura H, Shirane R, Yoshimoto T, Tominaga T. Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma. Journal of neuro-oncology 2004. link 30 Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Annals of the New York Academy of Sciences 2003. link 31 Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer investigation 2002. link 32 Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK et al.. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. International journal of radiation oncology, biology, physics 1999. link00266-1) 33 Crosby TD, Melcher AA, Wetherall S, Brockway S, Burnet NG. A comparison of two planning techniques for radiotherapy of high grade astrocytomas. Clinical oncology (Royal College of Radiologists (Great Britain)) 1998. link80038-1) 34 Steltzer KJ, Sauvé KI, Spence AM, Griffin TW, Berger MS. Corpus callosum involvement as a prognostic factor for patients with high-grade astrocytoma. International journal of radiation oncology, biology, physics 1997. link00632-3) 35 Pickles T, Goodman GB, Rheaume DE, Duncan GG, Fryer CJ, Bhimji S et al.. Pion radiation for high grade astrocytoma: results of a randomized study. International journal of radiation oncology, biology, physics 1997. link00542-1) 36 Campbell JW, Pollack IF, Martinez AJ, Shultz B. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996. link 37 Finlay JL, Boyett JM, Yates AJ, Wisoff JH, Milstein JM, Geyer JR et al.. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995. link 38 Fuentes R, Izquierdo AX, Canals E, Vayreda J, Dorca J, Beltrán M et al.. Neurological assessment of high grade astrocytomas following high dose radiotherapy as sole treatment. Clinical oncology (Royal College of Radiologists (Great Britain)) 1995. link80812-x) 39 Finlay JL, Geyer JR, Turski PA, Yates AJ, Boyett JM, Allen JC et al.. Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945. Journal of neuro-oncology 1994. link

High grade astrocytoma of brain